-
Vanderbilt-Discovered Compound Advances to Phase 1 Clinical Trial as a Promising New Treatment for Schizophrenia
Neumora Therapeutics, Inc. has announced the launch of a Phase 1 clinical study evaluating NMRA-861 in healthy adult participants and adults with stable schizophrenia.